Imaflex Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Imaflex hat ein Gesamteigenkapital von CA$58.0M und eine Gesamtverschuldung von CA$5.3M, wodurch sich der Verschuldungsgrad auf 9.1% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen CA$85.0M bzw. CA$26.9M. Imaflex Das EBIT des Unternehmens beträgt CA$3.6M, so dass der Zinsdeckungsgrad 6.1 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von CA$887.0K.

Wichtige Informationen

0.9%

Verhältnis von Schulden zu Eigenkapital

CA$560.00k

Verschuldung

Zinsdeckungsgrad	9.4x
Bargeld	CA$687.00k
Eigenkapital	CA$61.62m
Gesamtverbindlichkeiten	CA$22.49m
Gesamtvermögen	CA$84.11m

Jüngste Berichte zur Finanzlage

Recent updates

Imaflex (CVE:IFX) Is Reinvesting At Lower Rates Of Return

Aug 29

Market Might Still Lack Some Conviction On Imaflex Inc. (CVE:IFX) Even After 28% Share Price Boost

Aug 29

Revenues Not Telling The Story For Imaflex Inc. (CVE:IFX) After Shares Rise 48%

Jun 13

There May Be Some Bright Spots In Imaflex's (CVE:IFX) Earnings

Jun 05

Imaflex (CVE:IFX) Might Be Having Difficulty Using Its Capital Effectively

Jan 06

Is Imaflex (CVE:IFX) A Risky Investment?

Nov 25

Does Imaflex (CVE:IFX) Deserve A Spot On Your Watchlist?

May 25

We Think Imaflex (CVE:IFX) Can Stay On Top Of Its Debt

Mar 14

Does Imaflex (CVE:IFX) Have A Healthy Balance Sheet?

Aug 24

Is It Too Late To Consider Buying Imaflex Inc. (CVE:IFX)?

May 10

Imaflex (CVE:IFX) Could Easily Take On More Debt

Oct 23

Investors Should Be Encouraged By Imaflex's (CVE:IFX) Returns On Capital

Sep 04

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imaflex Inc.'s (CVE:IFX) CEO For Now

Jun 10

Imaflex (CVE:IFX) Seems To Use Debt Rather Sparingly

Jun 03

Here's Why I Think Imaflex (CVE:IFX) Might Deserve Your Attention Today

Apr 19

Imaflex (CVE:IFX) Shareholders Will Want The ROCE Trajectory To Continue

Mar 30

Did Imaflex Inc. (CVE:IFX) Insiders Sell Shares?

Mar 01

Is Imaflex Inc.'s (CVE:IFX) Latest Stock Performance A Reflection Of Its Financial Health?

Feb 04

Is Imaflex (CVE:IFX) A Risky Investment?

Jan 17

What We Make Of Imaflex's (CVE:IFX) Returns On Capital

Dec 30

Imaflex (CVE:IFX) Is Growing Earnings But Are They A Good Guide?

Dec 15

Have Insiders Sold Imaflex Inc. (CVE:IFX) Shares Recently?

Nov 30

What Does Imaflex's (CVE:IFX) CEO Pay Reveal?

Nov 26

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: IFXDie kurzfristigen Aktiva des Unternehmens (CA$34.3M) übersteigen seine kurzfristigen Passiva (CA$16.9M).

Langfristige Verbindlichkeiten: IFXDie kurzfristigen Vermögenswerte des Unternehmens (CA$34.3M) übersteigen seine langfristigen Verbindlichkeiten (CA$10.1M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: IFX über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: IFX Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 35.4% auf 9.1% zurückgegangen.

Schuldendeckung: IFXDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (1402.6%).

Zinsdeckung: IFXDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (6.1x Coverage) gut gedeckt.

Imaflex Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is Imaflex (CVE:IFX) A Risky Investment?

We Think Imaflex (CVE:IFX) Can Stay On Top Of Its Debt

Does Imaflex (CVE:IFX) Have A Healthy Balance Sheet?

Imaflex (CVE:IFX) Could Easily Take On More Debt

Imaflex (CVE:IFX) Seems To Use Debt Rather Sparingly

Is Imaflex (CVE:IFX) A Risky Investment?

Recent updates

Imaflex Inc. Announces CEO Changes, Effective October 28, 2024

Second quarter 2024 earnings released: EPS: CA$0.07 (vs CA$0.008 in 2Q 2023)

Imaflex (CVE:IFX) Is Reinvesting At Lower Rates Of Return

Market Might Still Lack Some Conviction On Imaflex Inc. (CVE:IFX) Even After 28% Share Price Boost

Investor sentiment improves as stock rises 24%

Revenues Not Telling The Story For Imaflex Inc. (CVE:IFX) After Shares Rise 48%

Investor sentiment improves as stock rises 18%

There May Be Some Bright Spots In Imaflex's (CVE:IFX) Earnings

First quarter 2024 earnings released: EPS: CA$0.04 (vs CA$0.018 in 1Q 2023)

Insufficient new directors

Full year 2023 earnings released: EPS: CA$0.01 (vs CA$0.18 in FY 2022)

Imaflex Inc., Annual General Meeting, Jun 13, 2024

Imaflex (CVE:IFX) Might Be Having Difficulty Using Its Capital Effectively

Third quarter 2023 earnings released: EPS: CA$0.003 (vs CA$0.06 in 3Q 2022)

Is Imaflex (CVE:IFX) A Risky Investment?

Second quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.066 in 2Q 2022)

Investor sentiment deteriorates as stock falls 18%

Insider recently sold CA$67k worth of stock

Imaflex Inc. Announces CEO Changes

Imaflex Inc. Appoints Roger Tambay as CEO

First quarter 2023 earnings released: EPS: CA$0.02 (vs CA$0.04 in 1Q 2022)

Imaflex Inc. Announces Chief Financial Officer Changes

Does Imaflex (CVE:IFX) Deserve A Spot On Your Watchlist?

Full year 2022 earnings released: EPS: CA$0.18 (vs CA$0.17 in FY 2021)

We Think Imaflex (CVE:IFX) Can Stay On Top Of Its Debt

Third quarter 2022 earnings released: EPS: CA$0.06 (vs CA$0.055 in 3Q 2021)

Imaflex Inc. Provides Earnings Guidance for the Full Year 2022

Price target increased to CA$1.95

Insufficient new directors

Imaflex Inc. Submits Advaseal® Registration Package to the EPA

Does Imaflex (CVE:IFX) Have A Healthy Balance Sheet?

Second quarter 2022 earnings released: EPS: CA$0.07 (vs CA$0.04 in 2Q 2021)

VP of Manufacturing recently sold CA$56k worth of stock

First quarter 2022 earnings released: EPS: CA$0.04 (vs CA$0.039 in 1Q 2021)

Is It Too Late To Consider Buying Imaflex Inc. (CVE:IFX)?

Price target increased to CA$1.95

Insufficient new directors

Imaflex Inc. Provides Earnings Guidance for the First Quarter 2022

Full year 2021 earnings released: EPS: CA$0.17 (vs CA$0.13 in FY 2020)

Imaflex Inc., Annual General Meeting, Jun 16, 2022

Imaflex Inc. Appoints Roberto Longo as Director, Chair the Audit Committee

Imaflex Inc. Announces Resignation of Mario Settino as Director

Vice-President of Corporate Affairs recently sold CA$56k worth of stock

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Imaflex (CVE:IFX) Could Easily Take On More Debt

Insider recently sold CA$520k worth of stock

VP of Manufacturing recently sold CA$98k worth of stock

Insider exercised options to buy CA$540k worth of stock.

Investors Should Be Encouraged By Imaflex's (CVE:IFX) Returns On Capital

Vice-President of Corporate Affairs exercised options to buy CA$735k worth of stock.

Second quarter 2021 earnings released: EPS CA$0.04 (vs CA$0.007 in 2Q 2020)

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imaflex Inc.'s (CVE:IFX) CEO For Now

Imaflex (CVE:IFX) Seems To Use Debt Rather Sparingly

First quarter 2021 earnings released: EPS CA$0.039 (vs CA$0.062 in 1Q 2020)

Here's Why I Think Imaflex (CVE:IFX) Might Deserve Your Attention Today

Full year 2020 earnings released: EPS CA$0.13 (vs CA$0.031 in FY 2019)

Investor sentiment improved over the past week

Imaflex (CVE:IFX) Shareholders Will Want The ROCE Trajectory To Continue

Did Imaflex Inc. (CVE:IFX) Insiders Sell Shares?

Is Imaflex Inc.'s (CVE:IFX) Latest Stock Performance A Reflection Of Its Financial Health?

Imaflex Announces Positive Independent Results for the ADVASEAL Release Study

New 90-day high: CA$1.22

Is Imaflex (CVE:IFX) A Risky Investment?

What We Make Of Imaflex's (CVE:IFX) Returns On Capital

Imaflex (CVE:IFX) Is Growing Earnings But Are They A Good Guide?

Have Insiders Sold Imaflex Inc. (CVE:IFX) Shares Recently?

Insider recently sold CA$108k worth of stock

Revenue beats expectations

Imaflex Inc. Updates on Its ADVASEAL Study